Industry coverage tracks the money around peptides: Eli Lilly and Novo Nordisk earnings, pipeline shifts, M&A, IPOs, peptide CDMO capacity, and the telehealth and pharmacy economy that GLP-1s built.
The two stories that keep moving the most market cap: how fast oral GLP-1s reach approval (orforglipron, oral semaglutide, oral wegovy, danuglipron's exit), and what happens to the compounded-peptide channel as the FDA tightens. Hims, Ro, LifeMD, GoodRx, and Amazon Pharmacy have all rerouted distribution in the past year. Behind them, contract manufacturers like Bachem, PolyPeptide, and BASF have been the bottleneck no one talked about until they were.
Stories here name the company, the deal, and the dollars. Earnings, partnership, regulatory hit — whatever moved the share price gets covered.
Axios reported Tuesday July 7, 2026 that blockchain analysis firm Chainalysis has identified a supply-chain shift in which Chinese manufacturers of fentanyl chemical precursors are pivoting into the US gray-market peptide trade. Q1 2026 crypto payments to gray-market peptide vendors reached $27 million, up nearly 150% from Q4 2025. One China-based company previously identified through its digital cryptocurrency wallet as a seller of fentanyl precursors reappeared on message boards selling cosmetic and weight-loss peptides. Chainalysis senior intelligence analyst Sara Graham characterized the shift bluntly: 'For these manufacturers that decided to pivot, it was really a business decision. They departed from a trade in which they could be sanctioned or indicted by the US and reappeared in a very lucrative scene that has widespread buy-in.' The pivot happens against a regulatory backdrop where compounded GLP-1 supply through 503B outsourcing facilities is closing (FDA proposed permanent exclusion of semaglutide, tirzepatide, and liraglutide from the 503B bulks list on April 30, 2026), pushing gray-market demand toward alternative channels. Traditional US banks and credit-card processors decline the peptide-vendor transactions, so crypto has become the dominant payment rail. The Chainalysis findings extend the earlier Fortune June 4 piece on the $100 million gray-market looksmaxxing peptide economy.
Kalohexis, the melanocortin-receptor peptide biotech spun out of Endevica Bio in March 2026, filed a confidential IPO application with the SEC this week. The company advances two lead assets on the melanocortin platform: 710GO, an oral dual MC3R/MC4R agonist that entered Phase 1 testing in Q2 2026 for general obesity; and mifomelatide, a dual MC3R/MC4R antagonist in Phase 2 development for cancer cachexia (severe weight loss and muscle wasting in patients with advanced cancer). The two programs run in opposite pharmacological directions on the same receptor family: 710GO activates MC3R/MC4R to reduce food intake and produce weight loss; mifomelatide blocks MC3R/MC4R to reverse cachexia-driven weight loss. Kalohexis's Nature Communications publication (June 2026) demonstrated that dual MC3R/MC4R activation drove substantial weight loss and reduced food intake in nonhuman primates without the cardiovascular safety risks that limited earlier melanocortin drug candidates. Data was also presented at ENDO 2026. The IPO filing signals investor appetite for non-GLP-1 obesity mechanisms as the melanocortin pathway becomes the highest-profile alternative to incretin biology.
On July 7, Vivani Medical announced a non-exclusive agreement letting Novo Nordisk evaluate NPM-139, a miniature ultra-long-acting semaglutide implant built on Vivani's NanoPortal technology and designed for once- or twice-yearly dosing. The deal grants no exclusivity over NPM-139 or the NanoPortal platform. It follows a June 25 Australian ethics-committee clearance for SLIM-1, a Phase 1 trial of NPM-139 that builds on Vivani's earlier NPM-119 exenatide implant.
Anodyne Nanotech closed a $12.6 million Series A, led by Velocity Partners, to advance ANN-101, a once-weekly GLP-1 skin patch, into first-in-human trials. The Boston company's HeroPatch solid-state microneedle platform delivers multi-milligram doses of peptides without injections or cold storage, aiming to reach the drug exposures obesity treatment requires. The round adds to a wave of investment in alternatives to weekly GLP-1 injections.
A Medical Daily report on July 6 found that eligible Part D beneficiaries are walking away from pharmacy counters without their GLP-1 prescriptions five days after the Bridge launched July 1. The rejections stem from a technical routing problem: when a pharmacy submits the claim through a patient's normal Part D plan, it is automatically denied. The fix is to route the claim through Humana's central processor using BIN 028918 and PCN MEDDGLP1BR, a detail many patients and pharmacists were unprepared for.
KFF (formerly Kaiser Family Foundation) published cost-projection detail on the Medicare GLP-1 Bridge demonstration this week that goes beyond the 3.8 million eligibility headline into the fiscal outlay Medicare actually books. The math: Medicare's net drug payment runs $195 per beneficiary per month ($245 negotiated net drug price minus the $50 patient copay). At 10% participation of the 3.8 million eligible Part D enrollees, monthly refills across the 18-month program cost Medicare roughly $1.3 billion; at 25% participation, $3.3 billion; at 50% participation, $6.7 billion; at 75% participation, $10 billion. CMS Medicare Director Chris Klomp told reporters on the launch call that the agency expects participation to run in the 'single-digit millions' at first with volume ramping through Q3 and Q4 2026, suggesting the middle of the KFF range as the most probable outcome. The Bridge operates outside the standard Part D risk pool, meaning Part D plan sponsors do not carry actuarial risk for these drugs; beneficiary spending under the Bridge does not count toward the Part D $2,100 annual out-of-pocket cap for 2026. The cost-projection frame is the piece analysts and Congressional staff will use to judge Bridge success over the next 18 months.
Novo Nordisk US Operations EVP Jamey Millar released a formal statement Wednesday July 1, 2026, framing the Medicare GLP-1 Bridge as 'an important step in getting Wegovy to more patients' and committing to continued work with CMS, healthcare professionals, pharmacists, and patient advocates on Bridge implementation. Millar's cardiovascular-outcome framing was the piece of the statement designed to distinguish Wegovy from competitor GLP-1s under the Bridge: 'Obesity is a serious, common chronic disease facing older Americans, and Wegovy is the only weight management medicine proven to reduce the risk of heart attack, stroke, or cardiovascular death in patients who also have known heart disease. That distinction matters for seniors age 65 and older, who have a high burden of both conditions.' The SELECT trial data (2023-2024) underpin the cardiovascular claim. The Bridge covers all doses and formulations of Wegovy injection (including the 7.2 mg Wegovy HD launched April 2026) and Wegovy pill (1.5, 4, 9, and 25 mg oral tablets, launched January 5, 2026 and reaching 3 million prescriptions by June 7). The program is available nationwide across all US states and territories through December 31, 2027. PharmExec and PR Newswire ran the announcement.
The Pep Club, a direct-to-consumer telehealth platform co-founded by entrepreneur Greg Yuna (CEO) and Gabriella Shak, publicly launched Tuesday June 30, 2026 at thepepclub.com with a full-stack model pairing prescription medication therapy and physician-guided peptide protocols with at-home biomarker testing. The platform spans more than a dozen categories including weight management (GLP-1 prescriptions), hormone optimization (testosterone, thyroid), sexual health (PT-141, sildenafil, tadalafil), hair restoration (finasteride, GHK-Cu, oral minoxidil), skin and acne (tretinoin, hyaluronic acid, cosmetic peptides), IV and vitamin support, peptides (BPC-157, TB-500, ipamorelin, sermorelin among the compounded offerings), and longevity. All protocols are reviewed and supervised by licensed clinicians and fulfilled through licensed pharmacy partners. The differentiator is the at-home capillary biomarker collection device that lets patients submit lab-quality panels for personalization and monitoring. Yuna, co-founder and CEO: 'When you combine real at-home testing with both prescription and peptide therapy under licensed clinical supervision, you can actually personalize treatment to the individual.' The platform launches into a competitive telehealth market that already includes Hims & Hers, LifeMD, Henry Meds, and Ro; the Pep Club differentiator is the peptide-plus-biomarker integration.
Day 2 of the Medicare GLP-1 Bridge demonstration ran through Thursday July 2, 2026 as the first prior-authorization submissions filed on Wednesday July 1 began flowing through Humana as central processor. CMS targets 72-hour turnaround on PA decisions, which puts the earliest Bridge-covered first fills at the pharmacy counter around Thursday July 3 to Friday July 4 for prescriptions submitted Wednesday. The wider first-fill wave is expected the week of July 6 as pharmacies complete Bridge-specific billing system setup using the Bridge BIN 028918 and PCN MEDDGLP1BR identifiers, and as prescribers gain familiarity with the eligibility-attestation workflow (BMI at start of GLP-1 therapy, absence of type 2 diabetes / moderate-to-severe OSA / MASH which would route to standard Part D instead). Humana's parallel role as the Limited Income Newly Eligible Transition (LI NET) program administrator provides operational infrastructure that CMS Medicare Director Chris Klomp cited on the Tuesday launch call as the reason the central-processor model can scale from Day 1 without a ramp-up window. Independent operational tracking through July will indicate whether the 72-hour PA target holds as volume builds.
KFF (formerly Kaiser Family Foundation) published an analysis estimating 3.8 million Medicare beneficiaries could have qualified for the Medicare GLP-1 Bridge in 2023 based on the three BMI-and-comorbidity eligibility tiers (BMI ≥35 no paired condition; BMI ≥30 with heart failure, uncontrolled hypertension, or chronic kidney disease; BMI ≥27 with pre-diabetes, prior MI, prior stroke, or symptomatic peripheral artery disease). CMS Medicare Director Chris Klomp told reporters on the launch call that the agency expects participation to run in the 'single-digit millions' at first, with volume ramping through Q3 and Q4 2026 as prescriber and pharmacy familiarity grows. Centene confirmed participation in the Bridge program despite the parallel delay in its Medicare Advantage pilot. The Bridge operates outside standard Part D risk pools; Part D plan sponsors do not carry risk for eligible GLP-1 drugs under the Bridge. Net drug pricing runs $245/month with CMS covering $195 and the patient paying the $50 copay.
The Medicare GLP-1 Bridge demonstration program launches Wednesday July 1, 2026 (one day from this digest), providing eligible Medicare Part D beneficiaries with $50/month access to Foundayo (orforglipron), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound KwikPen through December 31, 2027. Operationally, Humana opens its central-processor function for prior-authorization submissions and claims adjudication starting tomorrow; the Bridge-specific pharmacy billing identifiers (BIN 028918, PCN MEDDGLP1BR) become active for first fills. Walgreens published pharmacist-navigation guidance Tuesday flagging that store pharmacists will help Medicare patients verify eligibility (the three-tier BMI-and-comorbidity criteria walked through in this site's June 29 patient-guide insight), confirm Part D enrollment status, and submit the Bridge prior-authorization request to Humana through the dedicated workflow. CNN published a June 29 consumer explainer flagging that the program is the first time Medicare has paid for drugs prescribed solely for obesity. The Bridge runs in parallel with the broader BALANCE Model launching January 2027 in Part D, with the Bridge ending December 31, 2027 and beneficiaries transitioning to BALANCE.
Mainstream-media coverage of the Medicare GLP-1 Bridge demonstration intensified through the weekend ahead of Wednesday's July 1 launch. The Washington Post published 'Medicare is about to cover GLP-1 drugs for weight loss. Here's what to know' on June 29; CBS News ran a parallel explainer the same day; CNBC's June 28 piece flagged that a large share of eligible seniors may not yet know about the coverage expansion. The shared message across the three outlets: the program is the first time Medicare will help pay for drugs prescribed solely for obesity (rather than for diabetes, cardiovascular risk, or another approved indication), the $50/month copay applies to Foundayo (orforglipron tablets), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound KwikPen, the demonstration runs through December 31, 2027, and Humana acts as the single central processor for prior authorization and claims adjudication. CMS estimates several hundred thousand Medicare Part D beneficiaries will qualify under the three-tier BMI eligibility framework (BMI ≥35; BMI ≥30 with comorbid heart failure, uncontrolled hypertension, or chronic kidney disease; BMI ≥27 with prediabetes, prior MI, prior stroke, or peripheral artery disease). The Bridge transitions to the broader BALANCE Model launching January 2027 in Medicare Part D.
Zymeworks (NASDAQ: ZYME) announced Monday June 29, 2026 a definitive agreement to acquire Theravance Biopharma (NASDAQ: TBPH) for $17.00 per share in cash, an equity value of approximately $929 million plus a contingent value right (CVR) entitling Theravance shareholders to 80% of net proceeds from any future license, divestiture, or monetization of ampreloxetine (the late-stage program that posted topline results from the Phase 3 CYPRESS study on March 3, 2026, prompting the buyout window). The $17.00 price represents a 22% premium to Theravance's March 3 closing price and a 10% premium to the volume-weighted average price since that date. Financing comes from a $350 million non-recourse note secured by the US YUPELRI profit share from OMERS Life Sciences, plus Theravance's expected $360 million net cash balance at closing. The strategic anchor is YUPELRI (revefenacin), a once-daily nebulized long-acting muscarinic antagonist for COPD that competes against GSK's Trelegy, AstraZeneca's Bevespi, and Boehringer Ingelheim's Spiriva Respimat. The transaction is expected to close in H2 2026 subject to Theravance shareholder approval and regulatory clearances. Industry context: the deal sits inside a late-June biotech consolidation wave that also produced AbbVie's $10.9B Apogee Therapeutics acquisition (June 22, anti-IL-13 zumilokibart) and Sangamo's Chapter 11 with Lilly's $50M stalking-horse bid on capsid, zinc finger, MINT, and ST-506 prion-disease assets (June 23).
Analyst coverage of Hims & Hers (NYSE: HIMS) ahead of the July 23-24 PCAC meeting consolidated through the weekend with two distinct framings. Leerink Partners' Michael Cherny called the PCAC vote a 'modest binary event,' acknowledging that an affirmative outcome on BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, or Epitalon would open real upside starting FY2027 and beyond (peptides as a large new product category for the company's owned California compounding facility), while flagging the procedural caveat that PCAC votes have a mixed record and the FDA does not always follow committee recommendations. Canaccord Genuity reiterated a 'Buy' rating on HIMS with a $32 price target framing peptides as part of the company's long-term preventive-health, longevity, and wellness portfolio expansion. The two analyst views sit alongside Barclays' June 17 PT raise to $39 (Overweight, weight-loss-momentum thesis). HIMS stock entered Monday June 29 up roughly 29.79% in June despite a 1.62% intraday decline, with the convergence of analyst price targets and the binary July 23-24 PCAC catalyst positioning the company as one of the most-watched names in the obesity-and-longevity telehealth space heading into Q3 2026.
Fast Millennial Mode LLC, founded by entrepreneur Elena Catalina Radu, announced the official launch of Sacred Eye Beauty's flagship 30-Day Ritual on Sunday June 28, 2026. The system has two components. The Inside-Out Activator combines NAD+, spermidine, vitamin C, and MODS Max sublingual-delivery technology in a single daily dose targeting cellular-wellness and healthy-aging markers. The Skin Magic Tablets combine GHK-Cu (copper tripeptide-1), PQQ (pyrroloquinoline quinone), and methylene blue for skin and broader cellular support. The launch fits squarely inside the 2026 mainstream-consumer cosmetic peptide wave that this site has tracked across June: Moes Group's June 6 GHK-Cu private-label manufacturing rollout, CKYN's June 20 GHK-Cu launch, Cosmetics Business's June 2026 feature on eight peptide-anchored beauty launches (Shiseido Ultimune, YSE Beauty Xtreme Glow), and the K-beauty PDRN-peptide-exosome stack. Sacred Eye's differentiator is the inside-out positioning, pairing oral supplementation with topical-equivalent claims. The consumer-channel growth runs in parallel to the regulatory thread: GHK-Cu is one of the seven peptides on the FDA Pharmacy Compounding Advisory Committee's July 23-24 agenda for 503A bulks list eligibility.
STAT News' closing coverage of BIO 2026 in San Diego across two pieces, Alex Hogan's June 26 STATus Report and Damian Garde's June 25 key-takeaways feature, identified two organizing themes that emerged from the four-day convention. First, AI drug discovery shifted from investment-thesis territory to clinical-fact territory: Insilico Medicine's rentosertib (a TNIK inhibitor for idiopathic pulmonary fibrosis where both the target and the compound were identified by generative AI, not a human chemist) became the first peer-reviewed Phase IIa result for a fully AI-discovered drug when results were published in Nature Medicine in 2025 (60 mg once daily produced +98.4 mL mean FVC change versus -20.3 mL placebo across 71 patients). Second, biotech executives at BIO 2026 expressed structural anxiety about Chinese drug development that the industry's primary legislative response, the BIOSECURE Act, does not address: the concern is about the speed and depth of Chinese scientific output rather than about narrow IP or supply-chain risks. The convention's mood reportedly shifted notably from the depressed atmosphere at industry events in 2024-2025 (when capital markets were closed and FDA reviewer turnover was concerning) toward a more constructive engagement with the new operational reality.
Gene-editing pioneer Sangamo Therapeutics filed a voluntary Chapter 11 petition in the US Bankruptcy Court for the District of Delaware on Monday June 23, 2026, after disclosing only $27.6 million in cash as of March 31 and a May 2026 Nasdaq delisting for minimum-bid-price non-compliance. Two simultaneous asset purchase agreements established the floor. Eli Lilly is the stalking-horse bidder at $50 million cash plus assumption of certain liabilities for Sangamo's capsid delivery platform, zinc finger platform, modular integrase (MINT) platform, and prion disease program ST-506. Astellas Pharma takes the Fabry disease asset isaralgagene civaparvovec (ST-920) under a separate agreement. The Lilly bid covers the assets most relevant to the peptide-adjacent neurology pipeline, with prion protein biology offering platform optionality for Lilly's broader neurodegeneration program. Both agreements remain subject to higher-or-better offers under standard Section 363 sale procedures. Sangamo simultaneously cut 51 employees, approximately 40% of its remaining workforce, with the remainder retained through the auction and sale process. The bankruptcy closes a 30-year arc that began as the zinc-finger nuclease pioneer through gene editing's commercial first wave, and underscores that gene-editing platform capital is now consolidating into large-pharma hands.
Hims & Hers Health (NYSE: HIMS) is up roughly 25% in June 2026 on multiple converging investor signals heading into the final week of the month. Novo Nordisk leadership called Hims one of its most 'voluminous' telehealth partners on a recent earnings call, validating the March 2026 branded-supply pact that ended the prior compounded-GLP-1 litigation. Leerink reiterated its Market Perform rating ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting, framing peptides as the company's next major product category and a key 2027+ growth driver. Barclays raised its price target to $39 from $29 on June 17 with an Overweight rating. CEO Andrew Dudum confirmed Oura Ring integration is 'coming soon,' adding wearable connectivity to the platform. The Hims GLP-1 subscription stack now runs $39 for the first month and $149 monthly thereafter (excluding medication costs), with branded Novo Wegovy injections and pills available alongside the company's owned California compounding-pharmacy capacity for the post-PCAC peptide expansion. The convergence of investor signals (analyst PT raises, Novo validation, PCAC catalyst, wearable integration) makes HIMS one of the most-watched names in the obesity-and-longevity telehealth space heading into Q3 2026.